We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-9.94%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$218M
AUM Growth
-$1.85M
Cap. Flow
+$19.9M
Cap. Flow %
9.15%
Top 10 Hldgs %
83.54%
Holding
39
New
8
Increased
13
Reduced
2
Closed
16

Top Buys

1
CFMS
Conformis, Inc. Common Stock
CFMS
+$14.6M
2
ADMA icon
ADMA Biologics
ADMA
+$13M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$12.2M
4
EOLS icon
Evolus
EOLS
+$10.7M
5
OPTN
OptiNose
OPTN
+$8.58M

Top Sells

1
ADMS
Adamas Pharmaceuticals
ADMS
+$19.2M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$12.8M
3
GYRE icon
Gyre Therapeutics
GYRE
+$10.8M
4
SBBP
Strongbridge Biopharma plc.
SBBP
+$9.16M
5
AFMD
Affimed
AFMD
+$7.18M

Sector Composition

1 Healthcare 94.84%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$65.6M 30.08%
6,069,775
+268,027
+5% +$2.89M
CTIC
2
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$21.8M 10.02%
8,800,358
+836,029
+10% +$2.05M
XERS icon
3
Xeris Biopharma Holdings
XERS
$1.52B
$16.6M 7.61%
+5,656,373
New +$12.2M
ADMA icon
4
ADMA Biologics
ADMA
$2.02B
$14M 6.41%
+9,911,577
New +$13M
OVID icon
5
Ovid Therapeutics
OVID
$455M
$12.9M 5.9%
4,006,185
+753,293
+23% +$2.58M
EOLS icon
6
Evolus
EOLS
$377M
$12.1M 5.57%
1,863,096
+1,563,096
+521% +$10.7M
CFMS
7
DELISTED
Conformis, Inc. Common Stock
CFMS
$11.2M 5.16%
590,753
+571,274
+2,933% +$14.6M
XGN icon
8
Exagen
XGN
$106M
$9.98M 4.58%
858,567
+467,930
+120% +$5.48M
APEN
9
DELISTED
Apollo Endosurgery, Inc.
APEN
$9.7M 4.45%
1,151,163
+239,038
+26% +$2.09M
ATRS
10
DELISTED
Antares Pharma, Inc.
ATRS
$8.2M 3.76%
2,297,360
+2,033,260
+770% +$7.11M
OPTN
11
DELISTED
OptiNose
OPTN
$6.23M 2.86%
+256,282
New +$8.58M
DMAC icon
12
DiaMedica Therapeutics
DMAC
$393M
$4.46M 2.04%
1,194,670
+1,028,895
+621% +$4.04M
ATYR
13
aTyr Pharma
ATYR
$50M
$3.93M 1.8%
525,531
+114,996
+28% +$960K
RZLT icon
14
Rezolute
RZLT
$444M
$3.86M 1.77%
+808,405
New +$4.72M
CELC icon
15
Celcuity
CELC
$4.31B
$3.16M 1.45%
239,433
-55,259
-19% -$884K
CDTX
16
DELISTED
Cidara Therapeutics
CDTX
$2.94M 1.35%
115,577
+76,436
+195% +$2.38M
SYBX
17
DELISTED
Synlogic
SYBX
$2.58M 1.18%
70,942
+4,275
+6% +$166K
AVTX icon
18
Avalo Therapeutics
AVTX
$1.02B
$2.57M 1.18%
524
+229
+78% +$1.37M
ANIP icon
19
ANI Pharmaceuticals
ANIP
$1.8B
$2.41M 1.11%
+52,290
New +$2.25M
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
$1.01M 0.47%
+300,000
New +$1.14M
NMTC icon
21
NeuroOne Medical Technologies
NMTC
$20.4M
$967K 0.44%
+83,059
New +$1.34M
XOMA
22
DELISTED
Xoma
XOMA
$960K 0.44%
46,026
-22,516
-33% -$527K
ALDX icon
23
Aldeyra Therapeutics
ALDX
$102M
$800K 0.37%
+200,000
New +$1.53M
AFMD
24
DELISTED
Affimed
AFMD
– –
-116,147
Closed -$7.18M
ELTX icon
25
Elicio Therapeutics
ELTX
$81.7M
– –
-28,018
Closed -$2.74M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Stonepine Capital Management held 39 positions worth $218M, down 0.84% from $220M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Stonepine Capital Management deployed $19.9M of net new capital in Q4 2021, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was ADMA Biologics: 9,911,577 shares worth $14M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Celcuity, an estimated $884K trimmed.

  • Stonepine Capital Management's largest Q4 2021 buy was ADMA Biologics: 9,911,577 shares worth $14M.
  • Stonepine Capital Management added most to Conformis, Inc. Common Stock in Q4 2021, an estimated $14.6M increase.
  • Stonepine Capital Management's biggest Q4 2021 reduction was Celcuity, cutting an estimated $884K.
  • Stonepine Capital Management fully exited Adamas Pharmaceuticals in Q4 2021, selling an estimated $19.2M.
  • Stonepine Capital Management's ten largest holdings make up 84% of its $218M portfolio in Q4 2021.
  • Stonepine Capital Management opened 8 new positions and closed 16 in Q4 2021.
  • Stonepine Capital Management's portfolio value fell 0.84% quarter-over-quarter to $218M.

Based on Stonepine Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.